Stifel Nicolaus Begins Coverage on Crescent Biopharma (NASDAQ:CBIO)

Research analysts at Stifel Nicolaus assumed coverage on shares of Crescent Biopharma (NASDAQ:CBIOGet Free Report) in a research report issued to clients and investors on Wednesday, Marketbeat Ratings reports. The firm set a “buy” rating and a $28.00 price target on the biopharmaceutical company’s stock. Stifel Nicolaus’ target price indicates a potential upside of 65.68% from the stock’s current price.

A number of other equities research analysts have also recently issued reports on the stock. TD Cowen raised shares of Crescent Biopharma to a “strong-buy” rating in a report on Friday, June 20th. Lifesci Capital upgraded shares of Crescent Biopharma to a “strong-buy” rating and set a $22.00 price objective on the stock in a report on Wednesday, June 18th.

Check Out Our Latest Report on CBIO

Crescent Biopharma Trading Down 6.1%

Shares of CBIO stock opened at $16.90 on Wednesday. The stock has a market capitalization of $10.99 million, a PE ratio of -0.37 and a beta of 1.62. Crescent Biopharma has a 52-week low of $11.06 and a 52-week high of $63.00.

About Crescent Biopharma

(Get Free Report)

Crescent Biopharma, Inc operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.

Recommended Stories

Receive News & Ratings for Crescent Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crescent Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.